Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain (Delta-pain)
Primary Purpose
Cannabinoid, Tetrahydrocannabinol, Chronic Pancreatitis
Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Namisol
Diazepam
Sponsored by
About this trial
This is an interventional treatment trial for Cannabinoid
Eligibility Criteria
Inclusion Criteria:
- Patient has chronic pancreatitis, diagnosed using the Marseille and Cambridge Classification System (addendum II).37
- Patient suffers from chronic abdominal pain typical for pancreatitis, meet the criteria for chronic pain according ISAP (intermittent or persistent pain on a daily basis in at least 3 months)38, and consider their pain must as severe enough for medical treatment (average NRS ≥ 3).
- Patient in the opioid group takes stable doses of opioids, e.g. morphine or tramadol, for the past 2 months on the day of screening. Stable dose intake is defined as a daily equivalent sum of opioid intake according medical prescription within a small deviation range as judged by the (principal) investigator.
- Patient in the non-opioid group does not take any opioids for the past 2 months on the day of screening.
Exclusion Criteria:
- Patient used any cannabinoid (by smoking cannabis or oral intake) for at least one year on the day of screening.
- Patient does not feel a pinprick test in the lower extremities, due to affected sensory input (e.g. neuropathy as a result of diabetes mellitus).
- Patient has a body mass index (BMI) below 18 or above 31.2 kg/m2.
- Patient suffers from serious painful conditions other than chronic pancreatitis or had any major pre-existing chronic pain syndrome.
- Patient has a (history of) a significant medical disorder that, in the opinion of the investigator, may interfere with the study or may pose a risk for the patient.
- Patient uses any kind of concomitant medication that, in the opinion of the investigator, may interfere with the study or may pose a risk for the patient (e.g. HIV antivirals).
- Patient takes amitriptyline on a daily basis.
- Patient takes more than 20 mg benzodiazepines 6 hours prior or following intake of study medication (11 hour am) according prescription.
Sites / Locations
- Radboud University Nijmegen Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Namisol
Diazepam
Arm Description
Namisol (dronabinol) single dose 8 mg
Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Outcomes
Primary Outcome Measures
Pain intensity (VAS pain)
Pain intensity (VAS pain at rest and on movement)
Secondary Outcome Measures
EEG
Spontaneous EEG and evoked potentials to noxious electrical stimuli
QST
Quantitative Sensory Testing, using pressure pain tolerance and electrical thresholds
Body sway
Static body sway
Full Information
NCT ID
NCT01318369
First Posted
March 9, 2011
Last Updated
July 8, 2013
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01318369
Brief Title
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain
Acronym
Delta-pain
Official Title
The Safety, Tolerability, and Analgesic Efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain
Study Type
Interventional
2. Study Status
Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
May 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main goal of this trial is to study the efficacy of Namisol® after a single dose of Δ9-THC in the treatment of pain resulting from chronic pancreatitis. Objective measures of pain processing, e.g. encephalography (EEG) and quantitative sensory testing (QST), are included to provide insight in underlying nociceptive processing.
Detailed Description
The most important symptom in chronic pancreatitis (CP) is abdominal pain. Pancreatic pain is often recurrent, intense and long-lasting, and is extremely difficult to treat. Medical analgesic therapy is considered as first choice in pain management of CP, resulting in regularly prescription of opioids. The adverse consequences of prolonged opioid use, including addiction, tolerance and opioid induced hyperalgesia, call for an alternative medical treatment. Cannabis has been used to treat pain for many centuries. Delta-9-tetrahydrocannabinol (Δ9-THC), the psychoactive substance of the cannabis plant, has been shown in previous studies to be a promising analgesic. The development of Namisol®, a tablet containing purified Δ9-THC showing an improved and reliable pharmacokinetic profile, provides the opportunity to test the analgesic potential of Δ9-THC in favourable conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cannabinoid, Tetrahydrocannabinol, Chronic Pancreatitis, Abdominal Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Namisol
Arm Type
Experimental
Arm Description
Namisol (dronabinol) single dose 8 mg
Arm Title
Diazepam
Arm Type
Active Comparator
Arm Description
Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Intervention Type
Drug
Intervention Name(s)
Namisol
Other Intervention Name(s)
Dronabinol, THC
Intervention Description
Single dose delta-9-tetrahydrocannabinol
Intervention Type
Drug
Intervention Name(s)
Diazepam
Intervention Description
Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Primary Outcome Measure Information:
Title
Pain intensity (VAS pain)
Description
Pain intensity (VAS pain at rest and on movement)
Time Frame
Repeatedly; baseline until 6 hours after administration
Secondary Outcome Measure Information:
Title
EEG
Description
Spontaneous EEG and evoked potentials to noxious electrical stimuli
Time Frame
Repeatedly; baseline until 6 hours after administration
Title
QST
Description
Quantitative Sensory Testing, using pressure pain tolerance and electrical thresholds
Time Frame
Repeatedly; baseline until 6 hours after administration
Title
Body sway
Description
Static body sway
Time Frame
Repeatedly; baseline until 6 hours after administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient has chronic pancreatitis, diagnosed using the Marseille and Cambridge Classification System (addendum II).37
Patient suffers from chronic abdominal pain typical for pancreatitis, meet the criteria for chronic pain according ISAP (intermittent or persistent pain on a daily basis in at least 3 months)38, and consider their pain must as severe enough for medical treatment (average NRS ≥ 3).
Patient in the opioid group takes stable doses of opioids, e.g. morphine or tramadol, for the past 2 months on the day of screening. Stable dose intake is defined as a daily equivalent sum of opioid intake according medical prescription within a small deviation range as judged by the (principal) investigator.
Patient in the non-opioid group does not take any opioids for the past 2 months on the day of screening.
Exclusion Criteria:
Patient used any cannabinoid (by smoking cannabis or oral intake) for at least one year on the day of screening.
Patient does not feel a pinprick test in the lower extremities, due to affected sensory input (e.g. neuropathy as a result of diabetes mellitus).
Patient has a body mass index (BMI) below 18 or above 31.2 kg/m2.
Patient suffers from serious painful conditions other than chronic pancreatitis or had any major pre-existing chronic pain syndrome.
Patient has a (history of) a significant medical disorder that, in the opinion of the investigator, may interfere with the study or may pose a risk for the patient.
Patient uses any kind of concomitant medication that, in the opinion of the investigator, may interfere with the study or may pose a risk for the patient (e.g. HIV antivirals).
Patient takes amitriptyline on a daily basis.
Patient takes more than 20 mg benzodiazepines 6 hours prior or following intake of study medication (11 hour am) according prescription.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harry van Goor, MD PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Nijmegen Medical Centre
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain
We'll reach out to this number within 24 hrs